Get started
Author

Antonio Ucar

Observed names: A. Ucar, Ucar, Antonio
ORCID: 0000-0002-4562-7793
Observed ORCID: 0000-0002-4562-7793
OpenAlex ID: A5110179735
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial
2024 · Heinz-Josef Lenz, Aparna Parikh, et al. · Journal for ImmunoTherapy of Cancer · 74
PDF
Thrombotic microangiopathy and retroviral infections: A 13‐year experience
1994 · Antonio Ucar, Hugo F. Fernandez, et al. · American Journal of Hematology · 67
Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8.
2022 · Heinz-Josef Lenz, Aparna Raj Parikh, et al. · Journal of Clinical Oncology · 61
Induction Chemotherapy and Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy for Inoperable Pancreas Cancer
2022 · Michael D. Chuong, Roberto Herrera, et al. · Frontiers in Oncology · 44
PDF
A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma
2016 · Daniel W. Bowles, Mark Kochenderfer, et al. · Clinical Colorectal Cancer · 41
Clinical Spectrum of HTLV-I in South Florida
1995 · William J. Harrington, Antonio Ucar, et al. · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · 33
Causes of Death Among Patients With Initially Inoperable Pancreas Cancer After Induction Chemotherapy and Ablative 5-fraction Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy
2022 · Michael D. Chuong, Roberto Herrera, et al. · Advances in Radiation Oncology · 18
PDF
Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART)
2023 · JM Bryant, Russell F Palm, et al. · Cancer Control · 15
Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas
1994 · Bach Ardalan, Antonio Ucar, et al. · Cancer · 12
Irreversible Electroporation in Treating Colorectal Liver Metastases in Proximity to Critical Structures
2024 · Govindarajan Narayanan, Nicole T. Gentile, et al. · Journal of Vascular and Interventional Radiology · 11
Case report of ablative magnetic resonance-guided stereotactic body radiation therapy for oligometastatic mesenteric lymph nodes from bladder cancer
2020 · Michael D. Chuong, Diane Alvarez, et al. · Therapeutic Radiology and Oncology · 6
PDF
Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma
2023 · Samantha Webking, Maria L. Sandoval, et al. · Cancer Control · 5
Multi-Institutional Comparison of Ablative 5-Fraction Magnetic Resonance-Guided Online Adaptive Versus 15/25-Fraction Computed Tomography-Guided Moderately Hypofractionated Offline Adapted Radiation Therapy for Locally Advanced Pancreatic Cancer
2025 · Michael D. Chuong, Eileen M. O’Reilly, et al. · Cancers · 4
PDF
Multi-Institutional Comparison of Ablative Radiation Therapy in 5 Versus 15-25 Fractions for Locally Advanced Pancreatic Cancer
2022 · M. Reyngold, E. O'Reilly, et al. · International Journal of Radiation Oncology*Biology*Physics · 4
Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis.
2018 · Kenneth H. Yu, Simon Mantha, et al. · Journal of Clinical Oncology · 4
Sepsis and pancreatic cancer: Biliary stents a significant risk factor in patients undergoing chemotherapy.
2021 · Charles Charles Li, Amer H. Zureikat, et al. · Journal of Clinical Oncology · 3
Emerging Ablative and Transarterial Therapies for Pancreatic Cancer
2020 · Govindarajan Narayanan, Antonio Ucar, et al. · Digestive Disease Interventions · 3
PDF
Patterns of Failure After Definitive Ablative 5-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Ductal Adenocarcinoma
2026 · Michael D. Chuong, Roberto Herrera, et al. · International Journal of Radiation Oncology*Biology*Physics · 2
Abstract CT084: Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following Induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for unresectable locally advanced pancreatic cancer (TIGeR-PaC) - phase III trial interim analysis
2023 · Michael Pishvaian, Amer Zureikat, et al. · Cancer Research · 2
Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for unresectable locally advanced pancreatic cancer (TIGeR-PaC): A randomized phase 3 multicenter study.
2023 · Michael J. Pishvaian, Amer H. Zureikat, et al. · Journal of Clinical Oncology · 2
Phase III double-blinded, placebo-controlled study of MABp1 for improving survival in metastatic colorectal cancer.
2016 · Sanjay Goel, Lucjan Wyrwicz, et al. · Journal of Clinical Oncology · 2
Toxicity and efficacy of stereotactic body radiation therapy vs. intensity-modulated radiation therapy for the treatment of locally advanced pancreatic cancer in a phase 3 trial.
2023 · Karyn A. Goodman, Michael J. Pishvaian, et al. · Journal of Clinical Oncology · 1
Incidence and clinical characteristics of patients with LAPC and mesenteric vein thrombosis and current treatment paradigm.
2023 · Amer H. Zureikat, Michael J. Pishvaian, et al. · Journal of Clinical Oncology
PDF
Author response for "Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART)"
2022 · JM Bryant, Russell F Palm, et al.
Author response for "Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART)"
2022 · JM Bryant, Russell F Palm, et al.
Works count: 46
Citation count: 414
H-index: 10
I10-index: 10
Year
Topic
Type